Cargando…

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events

The optimal frequency of intravenous (IV) bisphosphonate administration is unclear. We thus performed a study evaluating the effects of switching from 3–4 to 12 weekly therapy in patients with biochemically defined low-risk bone metastases. Patients with serum C-telopeptide (CTx) levels ≤600 ng/L af...

Descripción completa

Detalles Bibliográficos
Autores principales:	Addison, Christina L., Bouganim, Nathaniel, Hilton, John, Vandermeer, Lisa, Dent, Susan, Amir, Eitan, Hopkins, Sean, Kuchuk, Iryna, Segal, Roanne, Song, Xinni, Gertler, Stan, Mazzarello, Sasha, Dranitsaris, George, Ooi, Daylily, Pond, Gregory, Clemons, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2014
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962742/ https://www.ncbi.nlm.nih.gov/pubmed/24638849 http://dx.doi.org/10.1007/s10549-014-2906-x

Ejemplares similares

Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases
por: Addison, Christina L, et al.
Publicado: (2014)

Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers
por: Kuchuk, Iryna, et al.
Publicado: (2013)

De-escalated administration of bone-targeted agents in patients with breast and prostate cancer—A survey of Canadian oncologists
por: Hutton, Brian, et al.
Publicado: (2013)

Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey
por: McGee, Sharon, et al.
Publicado: (2021)

Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases
por: Simos, Demetrios, et al.
Publicado: (2013)

Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists
por: Kuchuk, Iryna, et al.
Publicado: (2013)

Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer
por: Hilton, J.F., et al.
Publicado: (2017)

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer
por: Clemons, Mark, et al.
Publicado: (2021)

Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation
por: McGee, Sharon, et al.
Publicado: (2021)

Comparing the results of bisphosphonate use in clinical trials with actual practice: a case of apples and oranges?
por: Gainford, M.C., et al.
Publicado: (2006)

Strategies for obtaining bone biopsy specimens from breast cancer patients – Past experience and future directions
por: Ibrahim, Mohammed F.K., et al.
Publicado: (2016)

Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial)
por: Hilton, John, et al.
Publicado: (2018)

Does estrogen play a role in response to adjuvant bone-targeted therapies?
por: Russell, Kent, et al.
Publicado: (2013)

Incidence and consequences of bone metastases in lung cancer patients
por: Kuchuk, Michael, et al.
Publicado: (2013)

Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey
por: Hutton, Brian, et al.
Publicado: (2013)

Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression
por: KHALAF, DANIEL, et al.
Publicado: (2014)

Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers
por: Cole, Katherine Marie, et al.
Publicado: (2021)

Histomorphometric and microarchitectural analyses using the 2 mm bone marrow trephine in metastatic breast cancer patients–preliminary results
por: Fralick, M., et al.
Publicado: (2012)

Evaluating the Feasibility of Performing Window of Opportunity Trials in Breast Cancer
por: Arnaout, Angel, et al.
Publicado: (2015)

Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients
por: Beltran-Bless, A., et al.
Publicado: (2021)

A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer
por: Addison, C.L., et al.
Publicado: (2016)

A national portfolio of bone oncology trials—The Canadian experience in 2012
por: Kuchuk, I., et al.
Publicado: (2012)

Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey
por: AlZahrani, Mashari, et al.
Publicado: (2020)

Future directions for bone metastasis research – highlights from the 2015 bone and the Oncologist new updates conference (BONUS)
por: Fernandes, Ricardo, et al.
Publicado: (2016)

Bisphosphonate Treatment Alters the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta: A Pilot Study
por: Sithambaran, Siva, et al.
Publicado: (2022)

Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial
por: van Hellemond, Irene E. G., et al.
Publicado: (2020)

Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there?
por: Russell, Kent, et al.
Publicado: (2012)

Topical administration of regorafenib eye drops: phase I dose‐escalation study in healthy volunteers
por: Zimmermann, Torsten, et al.
Publicado: (2018)

Doxycycline-Induced Changes in Circulating MMP or TIMP2 Levels Are Not Associated with Skeletal-Related Event-Free or Overall Survival in Patients with Bone Metastases from Breast Cancer
por: Zhao, Huijun, et al.
Publicado: (2023)

Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre
por: Kuchuk, I., et al.
Publicado: (2013)

Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema
por: Dugel, Pravin U., et al.
Publicado: (2021)

De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study
por: Simons, J. M., et al.
Publicado: (2020)

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
por: Dezentjé, V. O., et al.
Publicado: (2015)

2207: A Phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer
por: Ezra Shabason, Jacob, et al.
Publicado: (2018)

Optimising weight-loss interventions in cancer patients—A systematic review and network meta-analysis
por: LeVasseur, Nathalie, et al.
Publicado: (2021)

Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
por: Cao, Junning, et al.
Publicado: (2017)

A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting
por: Clemons, M., et al.
Publicado: (2020)

Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting
por: Jacobs, Carmel, et al.
Publicado: (2015)

Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH)
por: Ostwal, Vikas, et al.
Publicado: (2022)

A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer
por: Dent, Susan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9c00uv7krg93asilithbgdef35